CY1120984T1 - Φαρμακευτικος συνδυασμος που περιεχει εναν αναστολεα κινασης φωσφατιδυλινοσιτολης-3 και εναν αναστολεα αρωματασης - Google Patents

Φαρμακευτικος συνδυασμος που περιεχει εναν αναστολεα κινασης φωσφατιδυλινοσιτολης-3 και εναν αναστολεα αρωματασης

Info

Publication number
CY1120984T1
CY1120984T1 CY181100927T CY181100927T CY1120984T1 CY 1120984 T1 CY1120984 T1 CY 1120984T1 CY 181100927 T CY181100927 T CY 181100927T CY 181100927 T CY181100927 T CY 181100927T CY 1120984 T1 CY1120984 T1 CY 1120984T1
Authority
CY
Cyprus
Prior art keywords
inhibitor
pharmaceutical combination
phosphatidylinositolis
fragrance
treatment
Prior art date
Application number
CY181100927T
Other languages
English (en)
Inventor
Michael Goldbrunner
Xizhong Huang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1120984T1 publication Critical patent/CY1120984T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά έναν φαρμακευτικό συνδυασμό που περιέχει μια ένωση παραγώγου 2- καρβοξαμιδο κυκλοαμινο ουρίας του τύπου (I) και τουλάχιστον έναν αναστολέα αρωματάσης για τη θεραπεία του καρκίνου, τις χρήσεις τέτοιων συνδυασμών στη θεραπεία του καρκίνου και μια μέθοδο θεραπείας των θερμόαιμων ζώων συμπεριλαμβανομένων των ανθρώπων που πάσχουν από καρκίνο με χορήγηση στο εν λόγω ζώο που έχει ανάγκη μια τέτοια θεραπεία μιας αποτελεσματικής δόσης μιας ένωσης παραγώγου 2- καρβοξαμιδο κυκλοαμινο ουρίας του τύπου (I) σε συνδυασμό με τουλάχιστον έναν αναστολέα αρωματάσης.
CY181100927T 2012-09-20 2018-09-05 Φαρμακευτικος συνδυασμος που περιεχει εναν αναστολεα κινασης φωσφατιδυλινοσιτολης-3 και εναν αναστολεα αρωματασης CY1120984T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261703533P 2012-09-20 2012-09-20
US201261708070P 2012-10-01 2012-10-01
PCT/US2013/060292 WO2014047109A1 (en) 2012-09-20 2013-09-18 Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor|and an aromatase inhibitor

Publications (1)

Publication Number Publication Date
CY1120984T1 true CY1120984T1 (el) 2019-12-11

Family

ID=49263471

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181100927T CY1120984T1 (el) 2012-09-20 2018-09-05 Φαρμακευτικος συνδυασμος που περιεχει εναν αναστολεα κινασης φωσφατιδυλινοσιτολης-3 και εναν αναστολεα αρωματασης

Country Status (21)

Country Link
US (1) US9532982B2 (el)
EP (1) EP2897644B1 (el)
JP (1) JP6212563B2 (el)
KR (1) KR102220965B1 (el)
CN (1) CN104661681B (el)
AU (1) AU2013318205B2 (el)
BR (1) BR112015004152A2 (el)
CA (1) CA2880506C (el)
CY (1) CY1120984T1 (el)
DK (1) DK2897644T3 (el)
ES (1) ES2686689T3 (el)
HR (1) HRP20181413T1 (el)
HU (1) HUE040520T2 (el)
IN (1) IN2015DN00735A (el)
LT (1) LT2897644T (el)
MX (1) MX356278B (el)
PL (1) PL2897644T3 (el)
PT (1) PT2897644T (el)
RU (1) RU2651023C2 (el)
SI (1) SI2897644T1 (el)
WO (1) WO2014047109A1 (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015172085A2 (en) * 2014-05-09 2015-11-12 Memorial Sloan-Kettering Cancer Center Biomarkers for response to pi3k inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101939319A (zh) * 2007-12-20 2011-01-05 诺瓦提斯公司 联噻唑衍生物、它们的制备方法以及它们作为药物的用途
PA8809001A1 (es) * 2007-12-20 2009-07-23 Novartis Ag Compuestos organicos
US20110178070A1 (en) * 2008-06-24 2011-07-21 Takeda Pharmaceutical Company Limited PI3K/mTOR INHIBITORS
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8293753B2 (en) * 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas

Also Published As

Publication number Publication date
SI2897644T1 (sl) 2018-10-30
AU2013318205A1 (en) 2015-02-26
IN2015DN00735A (el) 2015-07-10
RU2651023C2 (ru) 2018-04-18
HRP20181413T1 (hr) 2018-10-19
HUE040520T2 (hu) 2019-03-28
EP2897644B1 (en) 2018-06-06
ES2686689T3 (es) 2018-10-19
PT2897644T (pt) 2018-10-16
MX356278B (es) 2018-05-22
JP6212563B2 (ja) 2017-10-11
KR102220965B1 (ko) 2021-02-26
US20150231124A1 (en) 2015-08-20
AU2013318205B2 (en) 2016-05-19
RU2015111171A (ru) 2016-11-10
PL2897644T3 (pl) 2018-11-30
JP2015532927A (ja) 2015-11-16
CA2880506C (en) 2021-04-20
EP2897644A1 (en) 2015-07-29
CN104661681B (zh) 2018-07-03
MX2015003657A (es) 2015-06-05
CN104661681A (zh) 2015-05-27
DK2897644T3 (en) 2018-09-10
KR20150056778A (ko) 2015-05-27
WO2014047109A1 (en) 2014-03-27
BR112015004152A2 (pt) 2017-07-04
LT2897644T (lt) 2018-09-25
CA2880506A1 (en) 2014-03-27
US9532982B2 (en) 2017-01-03

Similar Documents

Publication Publication Date Title
CY1122480T1 (el) Μεθυλικη βαρδοξολονη για τη θεραπεια παχυσαρκιας
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
CY1123388T1 (el) Υποκατεστημενου νικοτινιμιδιου αναστολεις της βτκ και παρασκευη αυτων και χρηση στη θεραπεια καρκινου, φλεγμονης και αυτοανοσης ασθενειας
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1124298T1 (el) Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet
CY1124998T1 (el) Ετεροκυκλικες ενωσεις και χρήσεις αυτων
CY1121144T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
CY1122671T1 (el) Θεραπευτικως δραστικες ενωσεις και οι μεθοδοι χρησεις αυτων
CY1122984T1 (el) Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους
CY1120703T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
CY1120503T1 (el) Συνθεσεις οι οποιες περιλαμβανουν ζολεδρονικο οξυ ή σχετικες ενωσεις για ανακουφιση φλεγμονωδους πονου και σχετικων παθησεων
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
EA201691354A1 (ru) Терапевтические ингибирующие соединения
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
CY1123033T1 (el) Σπειροκυκλικοι αναστολεις της καθεψινης c
CY1115902T1 (el) Συνδυαστικη θεραπεια καρκινου με ανασταλτικες ενωσεις hps90
EA202092456A2 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
DOP2016000071A (es) Inhibidores de tirosina cinasa de bruton
EA201691155A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
EA201690753A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
CY1120751T1 (el) Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων